Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Sales and Divestitures (2016)

Historic Gains from Sales and Divestitures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q4 2016 value amounting to $52668.0.

  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures fell 8853.07% to $52668.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $52668.0, marking a year-over-year decrease of 8853.07%. This contributed to the annual value of $52668.0 for FY2016, which is 8853.07% down from last year.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures amounted to $52668.0 in Q4 2016, which was down 8853.07% from $154308.0 recorded in Q3 2016.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures registered a high of $459208.0 during Q4 2015, and its lowest value of $2352.0 during Q1 2016.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $154308.0 (2016), whereas its average is $200390.3.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first skyrocketed by 6118.61% in 2015, then tumbled by 9815.19% in 2016.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures (Quarter) stood at $284893.0 in 2014, then soared by 61.19% to $459208.0 in 2015, then tumbled by 88.53% to $52668.0 in 2016.
  • Its Gains from Sales and Divestitures stands at $52668.0 for Q4 2016, versus $154308.0 for Q3 2016 and $128956.0 for Q2 2016.